315 related articles for article (PubMed ID: 32752136)
1. Chemical Screening of Nuclear Receptor Modulators.
Ishigami-Yuasa M; Kagechika H
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752136
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.
Wang L; Si P; Sheng Y; Chen Y; Wan P; Shen X; Tang Y; Chen L; Li W
Chem Biol Drug Des; 2015 Apr; 85(4):481-7. PubMed ID: 25228339
[TBL] [Abstract][Full Text] [Related]
3. Importance of the pharmacological profile of the bound ligand in enrichment on nuclear receptors: toward the use of experimentally validated decoy ligands.
Lagarde N; Zagury JF; Montes M
J Chem Inf Model; 2014 Oct; 54(10):2915-44. PubMed ID: 25250508
[TBL] [Abstract][Full Text] [Related]
4. Structure-based discovery of antagonists of nuclear receptor LRH-1.
Benod C; Carlsson J; Uthayaruban R; Hwang P; Irwin JJ; Doak AK; Shoichet BK; Sablin EP; Fletterick RJ
J Biol Chem; 2013 Jul; 288(27):19830-44. PubMed ID: 23667258
[TBL] [Abstract][Full Text] [Related]
5. Nuclear receptors and their selective pharmacologic modulators.
Burris TP; Solt LA; Wang Y; Crumbley C; Banerjee S; Griffett K; Lundasen T; Hughes T; Kojetin DJ
Pharmacol Rev; 2013 Apr; 65(2):710-78. PubMed ID: 23457206
[TBL] [Abstract][Full Text] [Related]
6. Orphan nuclear receptor modulators.
Mohan R; Heyman RA
Curr Top Med Chem; 2003; 3(14):1637-47. PubMed ID: 14683519
[TBL] [Abstract][Full Text] [Related]
7. Rational discovery of novel type-III FTF antagonists to competitively suppress TIF-2 coactivation in liver cancer.
Xu L; Chen Z; Shao K; Wang Y; Cui L; Guo N
J Recept Signal Transduct Res; 2019 Aug; 39(4):304-311. PubMed ID: 31755335
[TBL] [Abstract][Full Text] [Related]
8. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.
Merk D; Steinhilber D; Schubert-Zsilavecz M
Future Med Chem; 2012 May; 4(8):1015-36. PubMed ID: 22650242
[TBL] [Abstract][Full Text] [Related]
9. Hybrid Reporter Gene Assays: Versatile In Vitro Tools to Characterize Nuclear Receptor Modulators.
Heering J; Merk D
Methods Mol Biol; 2019; 1966():175-192. PubMed ID: 31041747
[TBL] [Abstract][Full Text] [Related]
10. Current in vitro high throughput screening approaches to assess nuclear receptor activation.
Raucy JL; Lasker JM
Curr Drug Metab; 2010 Nov; 11(9):806-14. PubMed ID: 21189134
[TBL] [Abstract][Full Text] [Related]
11. Development of Nuclear Receptor Modulators.
Schierle S; Merk D
Methods Mol Biol; 2018; 1824():245-260. PubMed ID: 30039411
[TBL] [Abstract][Full Text] [Related]
12. Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery.
Kojetin DJ; Burris TP
Mol Pharmacol; 2013 Jan; 83(1):1-8. PubMed ID: 22869589
[TBL] [Abstract][Full Text] [Related]
13. Quantitative high-throughput identification of drugs as modulators of human constitutive androstane receptor.
Lynch C; Zhao J; Huang R; Xiao J; Li L; Heyward S; Xia M; Wang H
Sci Rep; 2015 May; 5():10405. PubMed ID: 25993555
[TBL] [Abstract][Full Text] [Related]
14. An Integrated Approach for Screening and Identification of Positive Allosteric Modulators of N-Methyl-D-Aspartate Receptors.
Jambrina E; Cerne R; Smith E; Scampavia L; Cuadrado M; Findlay J; Krambis MJ; Wakulchik M; Chase P; Brunavs M; Burris KD; Gallagher P; Spicer TP; Ursu D
J Biomol Screen; 2016 Jun; 21(5):468-79. PubMed ID: 26838761
[TBL] [Abstract][Full Text] [Related]
15. Validation of an optical microplate label-free platform in the screening of chemical libraries for direct binding to a nuclear receptor.
Vela L; Lowe PN; Gerstenmaier J; Laing LG; Stimmel JB; Orband-Miller LA; Martin JJ
Assay Drug Dev Technol; 2011 Oct; 9(5):532-48. PubMed ID: 21438675
[TBL] [Abstract][Full Text] [Related]
16. Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
Yu DD; Lin W; Chen T; Forman BM
Bioorg Med Chem; 2013 Jul; 21(14):4266-78. PubMed ID: 23688559
[TBL] [Abstract][Full Text] [Related]
17. Quantitative high-throughput screening assays for the discovery and development of SIRPĪ±-CD47 interaction inhibitors.
Miller TW; Amason JD; Garcin ED; Lamy L; Dranchak PK; Macarthur R; Braisted J; Rubin JS; Burgess TL; Farrell CL; Roberts DD; Inglese J
PLoS One; 2019; 14(7):e0218897. PubMed ID: 31276567
[TBL] [Abstract][Full Text] [Related]
18. Transactivation and Coactivator Recruitment Assays for Measuring Farnesoid X Receptor Activity.
Hsu CW; Zhao J; Xia M
Methods Mol Biol; 2016; 1473():43-53. PubMed ID: 27518622
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of selective modulators of nuclear receptor action.
Resche-Rigon M; Gronemeyer H
Curr Opin Chem Biol; 1998 Aug; 2(4):501-7. PubMed ID: 9736923
[TBL] [Abstract][Full Text] [Related]
20. Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR).
Chang TK; Waxman DJ
Drug Metab Rev; 2006; 38(1-2):51-73. PubMed ID: 16684648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
